Kalaris Therapeutics (KLRS) Preferred Stock Liabilities (2019 - 2020)
Kalaris Therapeutics (KLRS) has 2 years of Preferred Stock Liabilities data on record, last reported at $120.9 million in Q2 2020.
- For Q2 2020, Preferred Stock Liabilities changed 0.0% year-over-year to $120.9 million; the TTM value through Jun 2020 reached $120.9 million, changed 0.0%, while the annual FY2019 figure was $52.2 million, N/A changed from the prior year.
- Preferred Stock Liabilities reached $120.9 million in Q2 2020 per KLRS's latest filing, roughly flat from $120.9 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $120.9 million in Q2 2019 and bottomed at $52.2 million in Q3 2019.